In episode 245, Mike and James PREMIUM the listeners with talk about three new studies. Aleglitazar a new drug that was supposed to help people with type 2 diabetes, how best to use delayed antibiotic prescribing and a trial that answers the question about population screening for high cardiovascular risk patients.

Show notes

1) AleCardio – aleglitazar

JAMA 2014;311:1515-25

2) Delayed prescribing of antibiotics

BMJ 2014;348:g1606

3) INTER99 – Population screening and lifestyle counsellng

BMJ 2014;348:g3617

In episode 244, Mike and James continue to delve into issues around industry and discuss the costs of research, patent protection, and policies on industry relations. At the end we come to the conclusion that the phrase industry and us includes 2 people so everybody plays a role in the process.

Show notes

1) Industry and us

Handout for the references discussed in this podcast

2) Price Comparison of Commonly Prescribed Pharmaceuticals in Alberta 2014

In episode 243, Mike and James continue to delve into issues around industry and we now focus on how study design, selection of comparators and selective publication can impact the “truth”.

Show notes

 1) Industry and us 

Handout for the references discussed in this podcast

In episode 242, Mike and James continue to delve into the impact industry marketing has on how and why we prescribe. We get to the evidence around many of the influences and at the end we realize we are all influenced by many things and we are all biased – so deal with it by being aware of the influence.

Show notes

1) Industry and us 

Handout for the references discussed in this podcast